Precigen Announces First Patient Dosed In Phase 1/1b Study Of PRGN-3006 UltraCAR-T In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Higher Risk Myelodysplastic Syndrome (MDS)
Benzinga Newsdesk